CELLMOSAIC

Dr. Huang, a serial entrepreneur and technology developer with 25+ years in chemistry and biology, founded CellMosaic in 2008 (as CellMosaic LLC) to innovate in bioconjugation and drug delivery. She developed proprietary advanced bioconjugation processes for services, manufacturing, and commercialization of many unique products like PerKit and Antibody Drug Conjugation (ADC) kits. She invented several key platform technologies (AqT, OxLink™, SxLink™, and NeIon™) and has led CellMosaic to receive multiple awards. She also co-founded Alta Scientific, one of the leading suppliers of reference standards. She has multiple peer-reviewed publications and has helped CellMosaic secure 15 patents. Previously, she worked at Johnson Matthey Pharma Services and Ensemble Therapeutics. Dr. Huang is a reviewer for NIH contract grants and volunteers as a judge for FTC robotics competition. She earned her Ph.D. in Bioorganic Chemistry from Case Western Reserve University and conducted postdoctoral research in biology under Nobel Laureate H. Gobind Khorana at MIT. She holds an M.S. in Organic Chemistry from USTC and a B.S. from NanKai University. Yumei will be providing Form C sign-off as the Company's Principal Accounting Officer.

Dr. Dey, with 25+ years of experience in product commercialization, business and scientific management, chemistry, molecular biology, mass spectrometry, and clinical diagnostics, joined CellMosaic in 2019 to lead technology and new product development, diagnostic and therapeutic applications of AqT® technologies, and core intellectual property. He also oversees major projects and contributes to strategic planning and marketing. Previously, he was manager of IVD assay R&D at Sciex (Danaher Corp.) Clinical Diagnostics group and his team developed and launched the first Mass Spec. based FDA-cleared IVD assay. He played key roles in the Sciex policy deployment, product commercialization, and implemented the Danaher Business System to streamline assay development. He is the inventor of blockbuster proteomics and diagnostic reagents (iTRAQ® lines, Amplifex™ Keto, and Amplifex™ Diene). He has multiple patents, authored numerous publications, and holds awards. Dr. Dey earned his Ph.D. in Organic Chemistry from Case Western Reserve University and conducted postdoctoral research on nucleic acid chemistry at Northwestern Univ. He obtained his Master of Science in Chemistry from IIT Kanpur, India.

Annie, with 5+ years of biotechnology experience, specializing in biorepository management and clinical R&D sample testing, joined CellMosaic in Q2 of 2023 to support bioconjugation, bioanalysis, and product development. She is a key contributor in client projects, product development, and sustaining. Previously, she was a technical research assistant at Brigham and Women’s Hospital.

John, with over a decade of experience in R&D, organic synthesis, bioanalysis, and lab training, joined CellMosaic in Q1 of 2022. He oversees and supports product management, product manufacturing, inventory control and QC of the products. John plays a pivotal role in managing the company’s product portfolio and fulfillment.

Katie, a biochemistry graduate from Worcester Polytech. (WPI), joined CellMosaic in Q2 of 2022. She manages daily business operations and product sales, manages clients’ projects and performs bioconjugation related projects. As a technology enthusiast, she is also responsible for managing customer databases and marketing efforts.

CellMosaic’s IP-related matters are taken care of by Philip Zhang, PhD, J.D. Esq. Dr. Zhang is a co-founder and co-manager principal at Milstein Zhang & Wu LLC. Previously, he was a special counsel for Cooley Godward Kronish LLP, chief IP counsel for Ensemble Therapeutics, patent counsel for Genzyme, and patent attorney for Testa Hurwitz & Thibeault LLP. Dr. Zhang has helped CellMosaic with patent filing and overall patent strategies since the start of the company. He spends one to two hours a week on CellMosaic.